Maria-Clemencia Hernandez, PhD

Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Switzerland

  • 1Article
  • 1.1KReads
  • 2026Active
  • 8Collaborators

About

Maria-Clemencia Hernandez, PhD is affiliated with Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Switzerland. Maria-Clemencia Hernandez has contributed 1 peer-reviewed article published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders in 2026. Their work focuses on Cognition and Schizophrenia/Schizoaffective Disorders.

Publications

JCP
Phase 2b Study to Evaluate Basmisanil as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia
Original Research

Phase 2b Study to Evaluate Basmisanil as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia

April 15, 2026

Although basmisanil did not improve cognitive deficits, the results offer insight into factors that should facilitate design of more informative trials.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe